A Clinical Study of Islatravir and Its Interaction With Lamivudine (MK-8591-058)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 7, 2024

Primary Completion Date

July 14, 2024

Study Completion Date

July 14, 2024

Conditions

Healthy

Interventions

DRUG

Islatravir (ISL)

Oral administration of a single dose in period 1 and period 2

DRUG

Lamivudine (3TC)

Oral administration of multiple daily doses for 27 days

Trial Locations (1)

Celerion (Site 0001), Lincoln

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT06811246 - A Clinical Study of Islatravir and Its Interaction With Lamivudine (MK-8591-058) | Biotech Hunter | Biotech Hunter